Autolus Therapeutics plc (AUTL) Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Autolus Therapeutics plc NASDAQ:AUTL Healthcare · Biotechnology
Mkt Cap $404.57M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
Autolus Therapeutics will release third quarter 2026 financial results and operational highlights before U.S. market open on November 10, 2026.
Management will host a conference call and webcast at 8:30am EST / 1:30pm GMT the same day to discuss results and provide a general business update.
No financial figures or business developments are disclosed in this notice; it is purely a scheduling announcement.
• 6d ago AI analysis › Press Release
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Autolus Therapeutics will present updated CARLYSLE trial data for obe-cel in severe refractory systemic lupus erythematosus at ACR Convergence 2026 in Orlando.
The poster, scheduled for November 10, covers Phase 1 safety and efficacy results with up to 20 months of follow-up in adults and at least 3 months in adolescents.
This is a routine conference-abstract announcement with no new results disclosed; the actual data release in November is the event to watch for the autoimmune expansion of obe-cel beyond AUCATZYL in B-ALL.
• 27d ago AI analysis › Press Release ⚠ 2
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
The FDA granted RMAT (regenerative medicine advanced therapy) designation to Autolus Therapeutics' CAR-T therapy obe-cel for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN).
The designation, created under the 21st Century Cures Act, was granted based on Phase 1b data from the CARLYSLE trial and provides a framework for more efficient development within the pivotal Phase 2 LUMINA study.
The next CARLYSLE data update has been submitted for presentation at the ACR Annual Meeting in Q4 2026, while LUMINA continues enrolling refractory LN patients in five countries with data expected in 2028.
• 1mo ago AI analysis › Press Release ● Major ⚠ 1
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Autolus reported Q2 net product revenue of $45.7 million, up 119% year-over-year, with gross margin improving to 55% from 6% in the prior quarter.
The company raised full-year 2026 revenue guidance to $140-$150 million and secured a five-year, $250 million credit facility with Perceptive Advisors, extending its cash runway into Q2 2028.
Pipeline programs for obe-cel in lupus nephritis, pediatric ALL, and multiple sclerosis remain on track, with data readouts expected from late 2026 through 2028.
• 2mo ago AI analysis › Press Release
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
Autolus Therapeutics announced it will release its second quarter 2026 financial results and operational highlights before the market open on Tuesday, August 11, 2026.
Management is scheduled to host a conference call and webcast at 8:30am EDT to discuss the results and provide a general business update.
The company describes itself as a commercial-stage biopharmaceutical firm focused on next-generation programmed T cell therapies.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
Autolus reported preliminary Q2 revenue of approximately $45 million, up more than 100% year-over-year, and raised its FY 2026 sales guidance to $140 million–$150 million.
Gross margin improved significantly to approximately 35% year-to-date, marking a turnaround from the negative margins seen in the second half of 2025.
The company entered a five-year credit facility with Perceptive Advisors for up to $250 million, with $75 million funded upfront to extend its cash runway into Q2 2028.
• 2mo ago AI analysis › Press Release
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics granted inducement awards to 13 new employees, consisting of options to purchase 25,420 ADSs and 87,530 restricted stock units.
The awards were approved under Nasdaq Listing Rule 5635(c)(4) with an exercise price of $1.66 per share, equal to the closing price on June 23, 2026.
Both the stock options and RSUs vest over four years, subject to the employees' continued service with the company.
• 4mo ago AI analysis › Press Release
Autolus Therapeutics to Participate in Upcoming Investor Conference
Autolus Therapeutics plc announced that management will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.
Chief Executive Officer Dr. Christian Itin is scheduled to present in a fireside chat on Tuesday, June 30, 2026.
A live webcast of the presentation will be available on the company's website, with a replay archived for 90 days following the event.
• 4mo ago AI analysis › Press Release
Autolus Therapeutics Receives Prix Galien UK Award
Autolus Therapeutics has been awarded the 2026 Prix Galien UK Award for Best Biotechnology Product.
The award is presented by the Galien Foundation and selected by a committee of 12 UK healthcare experts.
Dr. Martin Pule, Founder and CSO, cited the company's mission to translate scientific research into patient treatments as the driver behind the recognition.
• 4mo ago AI analysis › Press Release
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics will present at William Blair’s 46th Annual Growth Stock Conference on June 2, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026.
CEO Dr. Christian Itin will lead presentations at both events, which will be webcast live and archived on the company’s investor relations website for 90 days.
The release serves as a standard calendar notification with no new operational or financial disclosures.
• 5mo ago AI analysis › Press Release
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Autolus Therapeutics will present post-hoc data from its Phase Ib/II FELIX study at the ASCO Annual Meeting, focusing on obe-cel in patients with relapsed/refractory B-ALL and extramedullary disease (EMD).
The analysis showed a 59% overall response rate and a median duration of response of 42.6 months in the EMD subset, a population typically associated with poorer outcomes.
These results reinforce the benefit-risk profile of AUCATZYL, Autolus' only currently marketed therapy, supporting its use in difficult-to-treat hematologic malignancies.
• 5mo ago AI analysis › Press Release ● Major ⚠ 2
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics reported net product revenue of $26.2 million for the first quarter of 2026, a significant increase from $9.0 million in the same period last year.
The company achieved a positive gross margin for the first time, driven by strong launches of AUCATZYL in the US and UK.
Autolus is implementing a cost reduction initiative, including a 13% workforce reduction, which is expected to reduce operating expenses by $15 million annually starting in 2027.
The company reiterates its full-year 2026 outlook for AUCATZYL net product revenue of $120 million to $135 million, up from $74 million in 2025.
• 5mo ago AI analysis › Press Release
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
Autolus Therapeutics announced it will release its first quarter 2026 financial results before the U.S. market open on Thursday, May 14, 2026.
Management will host a conference call and webcast at 8:30am EDT to discuss the results and provide a general business update.
The company is a commercial-stage biopharmaceutical firm focused on T cell therapies, including the marketed product AUCATZYL.
• 5mo ago AI analysis › Press Release ● Major ⚠ 1
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Autolus Therapeutics announced a strategic restructuring to improve operational efficiency, reducing its workforce by approximately 13% to cut costs while doubling manufacturing capacity for its commercial product in 2026.
The company reiterated its full-year 2026 revenue guidance for AUCATZYL of $120 million to $135 million, up from $74 million in 2025, and expects to shift to a positive gross margin this year.
These actions are projected to reduce operating expenses by $15 million on an annualized basis starting in 2027, extending the company's cash runway into the fourth quarter of 2027.
• 6mo ago AI analysis › Press Release
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus granted inducement awards consisting of 68,500 stock options and 57,765 restricted stock units to 15 new employees.
The stock options have an exercise price of $1.47 per share, which matches the closing stock price on April 13, 2026.
Both the options and RSUs vest over four years, subject to the employees' continued service with the company.
• 6mo ago AI analysis › Press Release
Autolus Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com • 6mo ago Press Release ● Major
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
globenewswire.com • 7mo ago 
